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Genetic vaccines are engineered to produce immunogens de novo in the cells of the host for stimulation of a protective immune response. In
some of these systems, antigens engineered for rapid degradation have produced an enhanced cellular immune response by more efficient entry
into pathways for processing and presentation of MHC class I peptides. VEE replicon particles (VRP), single cycle vaccine vectors derived from
Venezuelan equine encephalitis virus (VEE), are examined here for the effect of an increased rate of immunogen degradation on VRP vaccine
efficacy. VRP expressing the matrix capsid (MA/CA) portion of SIV Gag were altered to promote rapid degradation of MA/CA by various
linkages to co-translated ubiquitin or by destabilizing mutations and were used to immunize BALB/c mice for quantitation of anti-MA/CA cellular
and humoral immune responses. Rapid degradation by the N-end rule correlated with a dampened immune response relative to unmodified MA/
CA when the VRP carried a glycoprotein spike from an attenuated strain of VEE. In contrast, statistically equivalent numbers of IFNγ+T-cells
resulted when VRP expressing unstable MA/CA were packaged with the wild-type VEE glycoproteins. These results suggest that the cell types
targeted in vivo by VRP carrying mutant or wild type glycoprotein spikes are functionally different, and are consistent with previous findings
suggesting that wild-type VEE glycoproteins preferentially target professional antigen presenting cells that use peptides generated from the
degraded antigen for direct presentation on MHC.
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Many agents of human disease remain serious threats in the
absence of effective and affordable means of control or
treatment. However, there now exist powerful tools for
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doi:10.1016/j.virol.2007.08.020as well as for developing delivery systems to enhance their
immunogenicity and safety. New generation genetic vaccines,
that is, DNA plasmids or vaccine vectors that deliver genes
rather than proteins to the host, produce immunogens inside the
host's own cells for stimulation of a protective immune
response. These vaccines combine the safety features of subunit
vaccines, which carry immunogenic but not pathogenic
determinants of the disease agent, with the ability of a live
virus vaccine to present de novo synthesized proteins to the host
immune system. This is especially important for the stimulation
of a cellular immune response, in that newly synthesized
proteins can be processed for presentation on the host MHC
complexes in an authentic context.
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vectors can be gained through the use of different forms of
antigen. For example, antigens designed for more rapid
degradation may elicit an enhanced cellular immune response
by more efficient entry into pathways for processing and
presentation of MHC class I peptides in a professional antigen
presenting cell (APC). However, the effect of decreased protein
stability may not have this effect for vectors that target different
cells of the host immune system. Several studies of antigens
targeted for more rapid proteasomal degradation have found that
delivery of rapidly degraded antigens stimulates an enhanced
cellular immune response in vivo when delivered by DNA
vaccination (Andersson and Barry, 2004; Delogu et al., 2000;
Duan et al., 2006; Rodriguez et al., 1997, 1998; Wu and Kipps,
1997) or by recombinant vaccinia virus (Tobery and Siliciano,
1997; Townsend et al., 1988). As suggested previously by
several groups (Andersson and Barry, 2004; Huckriede et al.,
2004; Whitton et al., 1999), more efficient processing and
presentation of an antigen would be predicted to increase its
ability to induce a cellular immune response if the vector targets
a professional APC, and if production of appropriately processed
peptides from the unaltered antigen is the limiting step in
immune induction. If, however, the vector were to target a non-
APC and induce immunity by cross presentation, rapid antigen
degradation would be predicted to be unfavorable. In a series of
adoptive transfer experiments in mice, it was shown that the
transfer of intact proteins, not peptides, is optimal for cross
presentation when the antigen is expressed in a non-APC
(Norbury et al., 2004).
An increased rate of protein degradation can be achieved by
several different strategies, including ubiquitination, the N-end
rule, and mutations that affect protein folding. In the normal
proteasomal degradation pathway, proteins are targeted for
degradation by the 26S proteasome through the covalent
attachment of ubiquitin (Ub) to an internal lysine residue in the
target protein. This first step can be simulated artificially by
engineering a protein at the level of the gene sequence to carry a
co-translated, nonremovable N-terminal or internal Ub mono-
mer, thereby greatly increasing the efficiency of entry into the
degradation pathway. Alternatively, the N-end rule describes the
correlation between the half-life of a protein and the identity of its
N-terminal amino acid (Varshavsky, 1992). Certain N-terminal
amino acids, especially those with bulky or charged side-chains,
are destabilizing. The function of the N-end rule in targeting a
protein for more rapid degradation can be utilized by engineering
a protein to have a removable Ub moiety at the N-terminus,
which upon cleavage exposes the selected N-terminal residue of
the protein. Finally, an increased rate of protein degradation can
also be achieved by modifications which cause a protein to fold
improperly. The inherently high rate of misfolding which occurs
during protein synthesis makes it necessary for the cell to
eliminate these misfolded proteins to prevent the build-up of
toxic aggregates. This is accomplished primarily by proteasomal
degradation (Esser et al., 2004;Murata et al., 2001). Strategies to
induce protein misfolding in order to target the protein for rapid
degradation include sequence changes or rearrangements that
disrupt critical structural elements (Wong et al., 2004).A vaccine vector has been constructed based on the
alphavirus, Venezuelan equine encephalitis virus (VEE). The
VEE replicon particle (VRP) is a defective virus particle with a
self-replicating RNA genome lacking the structural protein
genes of the virus. VRP are packaged in trans using helper
RNAs that express VEE structural proteins, can program only a
single cycle of replication, and are unable to produce progeny
virus particles (Pushko et al., 1997). Studies in mice showed
that soon after inoculation VRP are found in the draining lymph
node, where they produce high levels of the heterologous
protein whose gene they carry (Grieder et al., 1995; MacDonald
and Johnston, 2000). VRP packaged with the wild type V3000
glycoproteins (VRP-3000) infect Langerhans-like cells at the
site of inoculation that then move rapidly to the draining lymph
node where they express surface markers found on APCs.
Specific mutations in the glycoprotein genes of the virus alter
the early steps in virus spread, probably due to changes in the
efficiency of infection of the Langerhans-like cell. The V3014
glycoprotein spike carries two mutations that attenuate VEE
virulence, but still allow efficient packaging of VRP (Grieder et
al., 1995; Pushko et al., 1997). VRP carrying the V3014 spike
as an added safety feature (VRP-3014) have been used in
several preclinical studies and in a human Phase I trial (Chulay,
2006). In continuing studies of VRP cell targeting in vivo,
preliminary results showed VRP-3014 primarily in cells that did
not exhibit the dendritic cell morphology or the localization in
the lymph node of the cell target for VRP-3000 (West, Johnson,
and Johnston, unpublished results).
To further characterize the VRP vector system, the effect of
antigen stability was examined using VRP packaged with wild
type or mutant glycoproteins. VRP expressing the matrix capsid
(MA/CA) portion of SIV Gag were altered to promote rapid
degradation of MA/CA by various linkages to co-translated Ub
or by destabilizing mutations, and were used to immunize
BALB/c mice for quantitation of anti-MA/CA cellular and
humoral immune responses.
Results
Targeting SIV MA/CA for rapid degradation
Initially, two strategies were used to target MA/CA for rapid
degradation, Ub fusion and the N-end rule (Fig. 1A). Ubiquitin
fusion was achieved by using a mutant ubiquitin with Val at
codon 76 to reduce the efficiency of removal of the Ub
monomer from the N-terminus of the fusion protein (Johnson et
al., 1992) and linking the Ub coding sequence in frame to the
MA/CA coding sequence in the VEE vector (Ub-V-MA/CA). In
a second configuration, the sequence encoding Ub-Val76 was
introduced in-frame between the sequences encoding Matrix
and Capsid (MA-UbV-CA). In both of these contexts, the
nonremovable Ub would serve as a substrate for rapid
polyubiquitination and would target the protein for subsequent
proteasomal degradation. Another strategy involved the N-end
rule, which describes the correlation between the half-life of a
protein and the identity of the N-terminal amino acid. Ub fusion
constructs in which the efficiently recognized Ub-Gly76
Fig. 1. (A) Diagram of VRP protein products used in this study. (B) Pulse-chase analysis of VRP-infected cells. VRP-infected BHK cells were starved for methionine
and cysteine from 4 to 5 hours post infection (hpi) and pulse labeled with 35S-Met and 35S-Cys for 30 min and then chased with an excess of unlabeled Met and Cys for
0 h, 2 h, 4 h, or 6 h before cell lysates were prepared and separated by SDS-PAGE and bands were quantitated by phosphorimager.
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methionine codon of MA/CA to be changed. Upon Ub
cleavage, the new N-terminal residue of MA/CA was exposed.
This approach was used to make MA/CA with a destabilizing
arginine N-terminal residue (Ub-R-MA/CA). The N-recognin/
E2 complex would recognize the arginine and mark an internal
lysine for ubiquitination (Meinnel et al., 2006; Varshavsky,
1996). The polyubiquitinated protein would then enter the
proteasomal degradation pathway.
Pulse-chase experiments demonstrated that each of the MA/
CA proteins engineered for rapid degradation had a shorter
half-life in cultured cells than the unmodified MA/CA (Fig.
1B). The N-end rule version of MA/CA, Ub-R-MA/CA, was
the most rapidly degraded with a t1/2 of 40 min compared with
the native MA/CA (N360 min). The Ub fusion proteins, Ub-V-
MA/CA and MA-UbV-CA, also had substantially decreased
half-lives of 77 min and 100 min, respectively. Both Ub fusion
proteins were slightly larger than the proteins produced by MA/
CA and Ub-R-MA/CAVRP due to their covalent linkage to the
76-residue Ub molecule. This is evident in Fig. 1B, as the
bands migrate slightly slower for Ub-V-MA/CA and MA-UbV-
CA. A faint lower band corresponding to the size of MA/CA is
also visible with Ub-V-MA/CA and MA-UbV-CA, which may
represent some leakiness of the Val76 cleavage site. In the
presence of the proteasome inhibitor lactacystin, degradation
kinetics for all of the constructs were similar to unmodified
MA/CA, indicating that the degradation of the N-end rule and
Ub fusion forms of MA/CA was proteasome dependent (data
not shown).Cellular immune response to rapidly degraded MA/CA
antigens
Several reports describe the effect of targeting antigens for
rapid degradation on the immune response using various
vaccine vectors. Initial experiments were performed to
determine what effect a rapidly degraded antigen would
have on the immune response when expressed from a VRP
vector packaged with a mutant glycoprotein spike (3014). The
3014 spike attenuates virulence in the context of VEE virus
and has been used as a safety feature in VRP vaccines
produced for pre-clinical and clinical trials. Mice were vac-
cinated with 106 infectious units (IU) of 3014-VRP expressing
MA/CA, Ub-R-MA/CA, or Ub-V-MA/CA. Four weeks later,
mice were boosted with the same dose. At 6 weeks after the
boost, mice were sacrificed, spleens were harvested, and
purified splenocytes were assayed by IFNγ-ELISPOT. For
each mouse, the median number of spots formed by
splenocytes stimulated with a pool of three SIV Gag peptides
(positive pool) less the average number of spots formed by
splenocytes incubated with an irrelevant peptide or no peptide
was plotted as spots per million cells in Fig. 2A. Mice
vaccinated with unstable forms of MA/CA (Ub-R-MA/CA or
Ub-V-MA/CA) displayed a significantly reduced cellular
immune response in comparison to mice vaccinated with
unmodified MA/CA (p=0.01 and p=0.01, respectively).
Decreasing stability of MA/CA also correlated with decreased
serum antibody responses at 1 week and 6 weeks after boost
measured by ELISA (data not shown).
Fig. 2. Groups of BALB/c mice were immunized subcutaneously in the rear footpads with 106 infectious units (IU) of VRP. At week 10, mice were sacrificed and
spleens removed. Splenocytes were purified and IFN-γ secreting cells were detected by ELISPOTassay in the presence of a pool of SIV Gag peptides. Each data point
represents spot forming cells per 106 cells for an individual mouse, and bars represent the median values. (A) ELISPOTassay at 10 weeks on spleen cells from BALB/c
mice immunized with 106 IU of 3014-VRP expressing MA/CA (♦), Ub-R-MA/CA (■), or Ub-V-MA/CA (▴). (B) ELISPOT assay at 10 weeks on spleen cells from
BALB/c mice immunized with 106 IU of 3000-VRP expressing MA/CA (◊), Ub-R-MA/CA (□),Ub-V-MA/CA (△), or MA-UbV-CA (○). (C) ELISPOT assay at
10 weeks on spleen cells from BALB/c mice immunized with 106 IU of 3014-VRP expressing MA/CA (♦) or Ub-R-MA/CA (■), or 3000-VRP expressing MA/CA
(◊) or Ub-R-MA/CA (□).
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antigens when administered in the context of the wild-type
glycoprotein coat
VRP particles packaged with different glycoprotein coats may
target different cells in vivo, and the wild type spike (GP3000)
targets to Langerhans-like dendritic cells, which then begin to
display surface markers of professional antigen-presenting cells
(MacDonald and Johnston, 2000). Based on these findings, the
immunogenicity of the ubiquitin-linkedMA/CA expressing VRP
when packaged using a glycoprotein helper RNA encoding the
wild-type VEE glycoprotein coat (VRP-3000) was assessed. In a
mouse experiment with the same dose and time line as the first
experiment, Ub-V-MA/CAandMA-UbV-CAVRP still induced a
weak cellular immune response in comparison to the unmodified
MA/CAVRP, but VRP expressing MA/CAwith a destabilizing
N-terminus, Ub-R-MA/CA, produced a response equivalent to
MA/CA (p-value did not reach statistical significance; Fig. 2B).
A second experiment directly comparing MA/CA and Ub-R-
MA/CA delivered by VRP-3014 or VRP-3000 at an identical
dose of 106 IU per mouse is described in Fig. 2C. As in the first
two experiments, expression of the rapidly degraded Ub-R-MA/
CA gave fewer IFNγ-expressing cells compared to unaltered
MA/CA-VRP in the 3014 coat, but a similar response when
packaged with the 3000 coat. Interestingly, the overall number of
IFNγ producing cells was higher, with borderline significance,
for unmodifiedMA/CAwhen given in the 3000 coat compared to
the 3014 coat (unadjusted p=0.048).VRP titer determination by real-time PCR
The V3014 mutant was isolated following stringent selection
for entry into cultured BHK cells (Johnston and Smith, 1988).
Further studies demonstrated that VRP-3014, but not VRP-
3000, use heparan sulfate to bind to BHK cells in culture
(Bernard et al., 2000). Based on this observation, it was
predicted that VRP-3014 would be more efficient at infecting
BHK cells than VRP-3000, and that their specific infectivities
(particle/IU) measured on BHK cells might differ. On the other
hand, efficiency of infection of target cells in vivo may be
governed by very different parameters than infection of BHK
cells. Therefore, to accurately compare the immune responses
induced by VRP packaged with V3014 or V3000 glycoproteins,
the titer of the VRP preparations was determined by an unbiased
method. A quantitative real-time PCR assay was developed to
quantify VRP genomes in samples of RNA extracted from
purified VRP preparations. Titers were calculated in genomes/
ml and compared with the BHK IU/ml titers (Table 1).
Replicons packaged in the 3014 glycoproteins gave similar
real-time PCR titers compared to the BHK infectivity titers,
indicating a high efficiency of infection of BHK cells.
Replicons packaged in the 3000 coat, however, had genome
titers approximately 100-fold higher than their corresponding
BHK titers, signifying that VRP-3000 have a lower efficiency
of infection in BHKs. In retrospect, the comparison of immune
responses shown in Fig. 2 was based on groups of mice
receiving either approximately 106 particles of VRP-3014 or
Table 1
Real-time PCR titers
Protein expressed GP
coat
BHK titer
(IU/ml)
Real-time PCR titer
(genomes/ml)
Genomes
per IU
MA/CA 3014 3.11×109 2.76×1010 8.9
MA/CA 3000 6.32×107 5.35×109 84.6
Ub-R-MA/CA 3014 5.44×109 1.92×1010 3.5
Ub-R-MA/CA 3000 1.04×108 1.33×1010 127.9
Fig. 3. ELISPOT assay at 10 weeks on spleen cells from BALB/c mice
immunized with 106 genome equivalents of 3014-VRP expressing MA/CA (♦)
or Ub-R-MA/CA (■), or 3000-VRP expressing MA/CA (◊) or Ub-R-MA/CA
(□). Each data point represents spot forming cells per 106 cells for an individual
mouse, and bars represent the median values.
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dose may explain the greater number of MA/CA-specific IFNγ-
secreting cells induced by MA/CA-expressing VRP-3000 than
MA/CA-expressing VRP-3014 (Fig. 2C).
Using the titers obtained from the real-time PCR assays,
groups of mice were inoculated with 106 genome equivalents of
VRP expressing stable or unstable forms of MA/CA packaged
with either the 3014 or the 3000 spike (Fig. 3). The numbers of
MA/CA-specific splenocytes, measured by IFNγ ELISPOT,
were not statistically different for unmodified MA/CA regard-
less of coat. However, the rapidly degraded form of MA/CA
was again associated with a decreased response compared to
stable MA/CA in the context of the 3014 spike (p=0.04). The
immunogenicity of the rapidly degraded Ub-R-MA/CA can be
compared in two different coats, and produced a significantly
better response in the 3000 coat than when given in the 3014
coat (p=0.009). Taken together, this suggests that the two
glycoprotein coats target functionally different cells.
When the dosage of VRP was adjusted for genome
equivalents, the absolute number of BHK-infectious units was
decreased approximately 100-fold for the 3000-VRP groups.
Interestingly, the decrease in dose did not produce a correspond-
ing decrease in the immune responses in the 3000-VRP
vaccinated groups (Figs. 2B, 2C and 3). It is possible that the
number of target cells for the VRP-3000 is limiting, and they are
all infected by the lower dose. An increased dose cannot
therefore give a proportional increase in the immune response.
Figs. 4A and B show the median antibody titers of the mice
from this experiment at week 4 and week 10. The antibody titers
to MA/CA were significantly decreased in the Ub-R-MA/CA
group compared to the MA/CA group with 3014-VRP, but not
3000-VRP, at both 4 weeks (pre-boost, p=0.00003) and
10 weeks (6 weeks after boost, p=0.001). These results reflect
the trends observed in the ELISPOT experiments, and indicate
that both the cellular and humoral responses to long-lived or
short half-life immunogens are affected similarly when
delivered by VRP-3014 or VRP-3000.
Mutations which cause misfolding and subsequent degradation
do not affect the immunogenicity of MA/CA in the wild-type
glycoprotein coat
Mutations which disrupt protein folding were introduced
into MA/CA (ufMA/CA) as another strategy to induce rapid
antigen degradation. In pulse-chase experiments, this form of
MA/CA was degraded with similar kinetics and to the same
extent as Ub-R-MA/CA (t1/2=55 min). However, in contrast toUb-R-MA/CA, the presence of the proteasome inhibitor
lactacystin did not prevent the degradation of ufMA/CA,
suggesting that degradation of this protein may occur in a
proteasome-independent manner. The characteristics of the
unfolding mutant provided an opportunity to examine the effect
of another, perhaps functionally different, antigen on the VRP-
induced immune response. ufMA/CA was compared to
unmodified MA/CA and Ub-R-MA/CA delivered by VRP-
3000 (Fig. 5). The MA/CA-specific cellular response, mea-
sured by IFNγ ELISPOT, was not statistically different for any
of the groups at 6 weeks after boost, indicating that rapid
antigen degradation caused by misfolding, like that caused by
the N-terminal Arg, does not result in the loss of a cellular
immune response when delivered by VRP with the wild type
glycoprotein spike.
Discussion
Several viruses are being modified and tested as vaccine
vectors, including VEE. The properties of VEE that would be
desirable in a vaccine vector include lack of anti-VEE immunity
in most humans, replication in the draining lymph node, known
attenuating mutations, and induction of mucosal immune
responses (Davis et al., 1994; Grieder et al., 1995; MacDonald
and Johnston, 2000; Thompson et al., 2006). In this study, a
VEE-derived vaccine vector, VRP, was characterized by
examining the effect of rapid antigen degradation on immuno-
genicity induced by VRP with different glycoprotein coats.
Forms of SIVMA/CAwith significantly reduced half-lives were
made using several strategies for targeted antigen degradation,
Fig. 4. Serum IgG titers from mice immunized with 106 genomes of MA/CA or Ub-R-MA/CA in either the 3014 or 3000 glycoprotein coat at week 4 (A, pre-boost)
and week 10 (B, 6 weeks post-boost) after the initial immunization. Points represent the median value of Log10 titers at half the maximum absorbance for each sample,
and error bars represent the range of values for each group.
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mutations. When compared to unmodified MA/CA, the rapidly
degraded forms of MA/CA resulted in a significantly reduced
cellular immune response in vaccinated mice when delivered by
VRP carrying the attenuated 3014 glycoprotein spike. This
result is consistent with similar studies using another alphavirus
vector, Semliki Forest Virus (rSFV), expressing a rapidlyFig. 5. Immunogenicity of MA/CA unfolding mutant. ELISPOT assay at
10 weeks on spleen cells from BALB/c mice immunized with 106 IU of 3000-
VRP expressing MA/CA (◊), Ub-R-MA/CA (□), or ufMA/CA (○). Each data
point represents spot forming cells per 106 cells for an individual mouse, and
bars represent the median values.degraded form of influenza nucleoprotein (NP) (Huckriede et
al., 2004). As was found with VRP-3014, the unstable ubiquitin-
NP fusion protein produced poor immune responses in mice
compared with the unmodified antigen, an outcome attributed to
the lack of dendritic cell infection seen with the rSFV vector.
These results with two alphavirus vectors are in contrast to
several previous studies, which used primarily DNA or
recombinant vaccinia virus vectors and reported successful
enhancement of cellular immune responses by targeted antigen
degradation.
When VRP were packaged with the wild type V3000 spike,
however, the correlation between rapid degradation of Ub-R-
MA/CA and poor immune response did not hold. In experiments
comparing equal IU doses of VRP expressing MA/CA and Ub-
R-MA/CA, the response to the rapidly degraded antigen was
equal or slightly increased compared to the unmodified antigen
when VRP carried the V3000 spike, but decreased with VRP-
3014 vaccination. Furthermore, a misfolded mutant of MA/CA,
which is also rapidly degraded, was able to induce a comparable
immune response to MA/CA and Ub-R-MA/CAwhen delivered
by VRP-3000. When these results are viewed in the context of
previous work done on the in vivo cell targeting of the VEE
glycoprotein coats (MacDonald and Johnston, 2000), it seems
likely that the difference in the effect of antigen stability
observed here is due to functional differences in the target cells.
As demonstrated previously (Norbury et al., 2004), rapid antigen
degradation has a detrimental effect on immunogenicity in the
context of cross-presentation, but not direct presentation. In fact,
the ideal substrates for cross priming were stably expressed
whole proteins. Based on these findings and the phenotypic
differences observed for VRP-3000 and VRP-3014 in this and
previous work, we suggest that the cells targeted by the wild type
and mutant glycoproteins differ in their antigen presentation
capabilities. Specifically, it appears that VRP-3014-infected
cells induce immune responses by cross-presentation of antigen,
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VRP-3014 expressed a rapidly degraded antigen.
If previous findings suggesting that V3000 infects an APC
are correct, then it could be predicted that a rapidly degraded
antigen delivered by VRP-3000 would enhance the response
over that induced by the stable form of the antigen. In one
experiment, a slight increase in immune response was correlated
with rapid antigen degradation, but this difference did not reach
statistical significance. In the second experiment, the number of
MA/CA-specific IFNγ-secreting splenocytes was not signifi-
cantly different for the stable and the unstable forms of antigen.
Therefore, it appears that the supply of peptides generated from
the high level protein expression directed by the VRP genome is
able to saturate a limiting number of MHC I complexes on the
VRP-3000-infected APC, and that increasing the efficiency of
protein processing does not increase the level of presentation.
Unexpectedly, the Ub fusion proteins Ub-V-MA/CA and
MA-UbV-CA differed from the N-end rule protein Ub-R-MA/
CA when delivered by VRP-3000. While these proteins were
also short-lived in vitro, they did not behave similarly to Ub-
R-MA/CA in vivo, and were less immunogenic than stable
MA/CA in both VRP-3014 and VRP-3000. These two Ub
fusion forms of MA/CA were destabilized by a different
strategy than Ub-R-MA/CA, which may explain the difference
in outcome. The mechanisms of entry into the Ub-proteasome
pathway are different for N-end rule proteins and Ub-fusion
proteins, which could potentially affect the efficiency of
processing. It is possible, although purely speculative, that
compartmentalized pathways for processing of peptides in the
VRP-3000 targeted cells work with different efficiencies on
proteasome substrates coming from the two rapid degradation
pathways, while these pathways are equivalent in the VRP-
3014 targeted cells.
Studies to characterize the in vivo target cells for VRP
enveloped in the two different spikes are ongoing, and results
obtained to date suggest that the V3000 glycoprotein spike
interacts with immature dendritic cells both in vivo (MacDonald
and Johnston, 2000) and in vitro (Moran et al., 2005). Cell
surface markers on VRP-3000-infected cells in the draining
lymph node indicated that the dendritic cells undergo only
partial maturation following VRP infection (MacDonald and
Johnston, 2000). Increasing the dose of VRP-3000 allowed
detection of infected cells with surface markers found on mature
DCs and macrophages. In vitro, VRP-3000-infected bone
marrow-derived dendritic cells display surface markers expected
of mature dendritic cells (CD80, CD86, and CD83), but also
secrete a constellation of pro-inflammatory cytokines (IFNα,
TNFα, IL-6, and IL-12p70) that are not secreted by mature DCs
(Moran et al., 2005). Therefore, VRP-3000 infection appears to
alter the maturation program of these cells, giving them unique
properties. In vitro infection of dendritic cell subsets with VRP-
3014 has been reported recently (Nishimoto et al., 2007).
However, until a direct comparison of VRP-3000 andVRP-3014
infection of dendritic cells in vitro is performed, it remains to be
seen whether distinct DC subsets of these cultured primary cells
are targeted by wild type and mutant glycoproteins. As further
work, both in vivo and in vitro, identifies the distinct cellulartargets for VRP-3000 andVRP-3014, differential viral effects on
protein degradation and peptide presentation pathways may also
be discovered.
In this study, the effects of specific infectivity differences
between VRP-3014 and VRP-3000 on their comparative
immunogenicity also were examined. Evidence that VRP
packaged in V3014 glycoproteins infect BHK cells more
efficiently than VRP-3000 suggested that titers based on BHK
infectious units may represent different numbers of particles in
each case. Determination of VRP titer by real-time PCR
confirmed this idea, and titers measured by BHK infectivity
underestimated the concentration of V3000 VRP by approxi-
mately two logs. However, the comparison of VRP expressing
either the unmodified MA/CA or Ub-R-MA/CA in the two coats
using a dose based on an equal number of genomes, instead of
BHK IU, showed the same trends in the effect of glycoprotein
spike on immunogenicity of stable and unstable MA/CA. In
addition, the differences in the magnitude of the responses to the
unmodified MA/CA in the two coats were eliminated when the
in vivo dose was adjusted based on genome quantitation. This
indicates that the different effects of antigen stability seen with
VRP-3000 and VRP-3014 are not due merely to quantitative
differences in infectious in vivo dose.
While the rapid antigen degradation approach has been used
with other vaccine vectors as a strategy to increase cellular
immune responses, it has consistently resulted in a substantial
corresponding loss of humoral responses (Andersson and Barry,
2004; Delogu et al., 2000; Fu et al., 1998; Rodriguez et al.,
1997; Wu and Kipps, 1997). In this study, the antibody
responses to the VRP-delivered rapidly degraded antigens
mirrored the cellular response in all groups. Based on previous
studies of rapidly degraded antigens, it was predicted that Ub-R-
MA/CAwould induce minimal antibody production, regardless
of glycoprotein coat, due to the rapid and complete degradation
observed in vitro. Surprisingly, in the 3000 coat, Ub-R-MA/CA
retained the ability to induce an antibody response. This
suggests that the cell(s) targeted by VRP-3000 may contribute
to the humoral immune response, at least in part, by presenting
peptides on MHC II, in which case rapid degradation would not
be detrimental.
VRP vaccine vectors are capable of stimulating robust
cellular and humoral immune responses in vivo, and in this
report we show that functional differences in the cellular targets
of VRP packaged in a mutant or wild type glycoprotein coat
can significantly influence the magnitude of these immune
responses. This suggests that optimization of these vectors for
immunization may involve, at a minimum, integrated evalua-
tion of both vector and immunogen configuration.
Materials and methods
Cells
Baby hamster kidney (BHK-21) cells were maintained in 1×
MEM-α (Minimal Essential Medium Alpha), supplemented
with 10% Donor Calf serum (DCS), 10% tryptose phosphate
broth, 2 mM L-Glutamine, and 100 U/ml each penicillin and
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incubator.
Plasmids
A mutant mouse Ub sequence, obtained from pCMV-U-
MG34, the kind gift of Lindsay Whitton (Rodriguez et al.,
1998), was amplified by PCR using primers designed to add a
unique ClaI restriction site upstream of the initiating ATG, as
well as preserve a unique EcoRI restriction site downstream of
the Ala codon 76. PCR was also used to amplify the SIVsm
H-4 Gag gene from a VEE replicon plasmid analogous to that
for SIVsm H-4i matrix-capsid (MA/CA) described previously
(Davis et al., 2000), using primers designed to add an EcoRI
restriction site upstream of the initial ATG of Gag, and a ClaI
site downstream of the Gag stop codon. This Gag gene carried
a change from Gly to Ala in codon 2 to ablate the myristylation
signal (Davis et al., 2000). In a third PCR reaction (overlap
reaction) the two PCR products were linked together to form a
DNA fragment with a single open reading frame encoding a
ubiquitin-Gag fusion protein flanked by ClaI restriction sites.
This fragment was inserted into the unique ClaI site of the
VEE replicon plasmid pVR2 (Pushko et al., 1997) to give
pVR2/Ub-Gag. Similar standard PCR protocols were used with
appropriate primers to alter the Ub-Gag fusion protein as
follows: (1) change the Ub mutant Ala76 to either Gly76 or
Val76, (2) substitute an Arg for the N-terminal Met of Gag, (3)
truncate the gag sequence at the 3′ end of the capsid region
leaving the coding sequence for MA/CA followed by a stop
codon, and (4) move the position of ubiquitin to an in-frame
insertion between the matrix and capsid sequences. Sequences
for each of these fusion proteins, as well as the nonmyristy-
lated, nonubiquitinated MA/CA region of SIV Gag were
inserted individually into the pVR2 replicon plasmid (as
diagrammed in Fig. 1A).
A second, closely related VEE replicon plasmid, pERK
(Kamrud et al., 2007), was used to express mutated forms of
MA/CA. The pERK replicon vector differs from pVR2 in that it
contains the 3′-most 16 nucleotides of the 5′ UTR of the 26S
subgenomic mRNA followed by a unique EcoRV site, and a
kanamycin resistance gene in place of the ampicillin resistance
gene. In previous work, VEE vectors with and without the 3′-
most 16 nucleotides of the 5′ UTR were engineered to express
the identical MA/CA sequence and shown to give equivalent
protein levels in primary mouse embryo fibroblasts (Cecil et al.,
2007). The nonmyristylated MA/CA sequence was amplified
using PCR with primers designed to add a downstream stop
codon and modified termini to allow insertion into the pERK
vector between the unique EcoRV and AscI sites to give the
plasmid pERK-MA/CA. The same MA/CA PCR product was
cloned into a PCR cloning plasmid to use as template for further
mutagenesis using the Quick-Change strategy of mutagenesis
(Stratagene). First, three nucleotide changes were introduced at
position 1154–1157 (numbering from the 5′ end of the
SIVsmH-4i genome; TGG to GAC, codon 36 of MA), changing
one codon from Tyr to Asp. This amino acid is located in helix2
of the MA globular domain (Massiah et al., 1994). A clone withthis mutation was then used as the template for a second round
of mutagenesis in which three nucleotides were changed from
TGG to GAC at position 1517–1519, which changed the CA
codon 23 from Tyr to Asp. This residue is located in helix I of
the N-terminal domain of CA. Trp23Ala (helix I) and Phe40Ala
(helix II) have been reported to disrupt CA structure and prevent
proper maturation of virus cores (Tang et al., 2001, 2003).
Finally, another three nucleotide changes were introduced at
position 1990–1992, which generated another Tyr to Asp
mutation in CA (HXB2 CA position 184). This residue is
located at the dimer interface of the CA C-terminal domain.
Trp184 is part of the hydrophobic core of the dimer interface
(Gitti et al., 1996; Momany et al., 1996), and a Trp184Ala
mutation had been reported to abolish CA dimerization (Mateu,
2002; von Schwedler et al., 2003). In all, a total of three codons
were changed in the MA/CA coding domain. The mutated MA/
CA was cloned into the pERK vector following the same
strategy as above. The new plasmid was designated pERK-
ufMA/CA.
Production and titration of VEE replicon particles (VRPS)
Plasmid DNA was prepared with the Qiagen HiSpeed
Plasmid Maxi Kit. DNA was linearized with NotI, and RNA
transcribed in vitro using the Ambion mMESSAGE mMA-
CHINE T7 kit. BHK cells were electroporated with a mixture of
three RNAs: replicon RNA, capsid helper RNA, and glycopro-
tein helper RNA (Pushko et al., 1997) using a BioRAD
GenePulser. Cells were pulsed three times at 850 V, 25-μF
capacitance. Harvest and purification of VRP by sedimentation
through a cushion of sucrose were performed as described
previously (Davis et al., 2000). VRP were titrated by infection
of BHK cells with serial dilutions of purified VRP for 16 h at
37 °C followed by a 10 min methanol fixation at 4 °C. Cells
were incubated with serum from mice vaccinated with null
VRP, which express the VEE replicase proteins but no foreign
gene. This serum contains antibody to VEE nonstructural
proteins present in VRP-infected cells. Cells were washed and
incubated with biotinylated anti-mouse IgG followed by
strepavidin conjugated to Alexaflour Texas Red. VRP-infected
cells were scored microscopically for fluorescence under UV
illumination.
Quantitative real-time PCR for VRP genomes
Purified VRP were serially diluted in phosphate-buffered
saline (PBS), and several dilutions were extracted using
MagMAX Viral RNA Isolation Kit (Ambion) according to
manufacturer's instructions. RNAwas treated with the TURBO
DNA-free kit (Ambion) to remove any contaminating genomic
DNA. Primers and probes for real-time PCR were designed
using Primer Express software (Applied Biosystems). The
forward primer V928F (GCCTGTATGGGAAGCCTTCA), the
reverse primer V1000R (TCTGTCACTTTGCAGCACAA-
GAAT), and the 5′FAM and 3′TAMRA labeled probe MEPnsp1
(CCTCGCGGTGCATCGTAGCAGC) (Integrated DNA Tech-
nologies) were used to detect a regionwithin the nsp1 gene of the
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Prism 7000. Real-time PCR reactions were set up in a total
volume of 25 μl including 5 μl RNA, 12.5 μl TaqMan One Step
RT-PCR Master Mix (ABI), 900 nM forward primer, 300 nM
reverse primer, 250 nM probe, and 0.625 μl MultiScribe Reverse
Transcriptase plus RNase Inhibitor. Cycling conditions were
48 °C for 30 min, 50 °C for 2 min, 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s and 60 °C for 1min. Samples were run
in duplicate. The threshold cycle was set manually and copy
number for each sample was determined using a standard curve
method. RNA transcripts for the standard curve were synthe-
sized from linearized pVR21 plasmid DNA by Ambion
mMESSAGE mMACHINE T7 kit. RNA was DNAse treated
and lithium chloride precipitated and the concentration was
determined by spectrophotometry.
Pulse-chase labeling of infected cells
BHK cells were plated in 12-well tissue culture dishes at 105
cells per well in BHK complete medium. The next day cells
were infected with VRP at an MOI of 5. Cells were incubated
for 4 h in complete medium and then washed and incubated in
methionine/cysteine-free MEM (MP Biomedicals) with 1%
DCS for 1 h. Medium was replaced with 0.5 ml methionine/
cysteine free MEM with 1% DCS with or without 10 μM
lactacystin (Sigma) and incubated for 30 min. Cells were
labeled with 50 μCi of 35S-methionine/cysteine per well
(Amersham) for 30 min. Label was removed, and cells were
washed twice with 0.5 ml of BHK complete medium followed
by the addition of 1 ml chase medium (complete BHK media
+4 mM unlabeled L-methionine and 4 mM L-cysteine, with or
without 10 μM lactacystin). Cells were either harvested directly
(0 h) or incubated for 2, 4, or 6 h (chase). Prior to harvest, cells
were washed twice with 1 ml cold PBS. Cells were harvested in
0.25 ml NP-40 lysis buffer (54 mM Tris, 170 mM NaCl, 13 mM
EDTA [pH 7.2]+0.2% igepal [NP-40]). Proteins in cell lysates
were separated by SDS-PAGE and analyzed by phosphorima-
ging (Molecular Dynamics). Half-lives of the heterologous
protein expressed from the VRP were determined by regression
analysis.
Immunizations of mice with VRP
VRP were diluted in PBS containing 100 mM calcium and
50 mM magnesium with 1% DCS, and groups of 5 to 6 week
old BALB/c mice were inoculated subcutaneously in both rear
footpads with a total of 106 IU unless otherwise noted. Mice
were boosted with the same dose 4 weeks after the primary
inoculation. Mice were bled prior to immunization (week 0),
prior to boost (week 4), and at weeks 5 and 10.
Harvest of spleen cells and ELISPOT assay
Multiscreen 96-well filtration plates (Millipore, ELIIP10SSP)
were coated overnight at 4 °C with 5 μg/ml anti-mouse IFN-γ
(Mabtech, AN18). Plates were washed with PBS and blocked
with 5% FBS in AIM V medium (Invitrogen). Spleens wereharvested and homogenized into single cell suspensions in
PBS+10% Alsever's solution (44.4 mM dextrose, 28.6 mM
citric acid, 71.9 mM sodium chloride). Cells were pelleted and
red blood cells were lysed by adding 1 ml of sterile water,
immediately followed by 10 ml of PBS/Alsever's (PBS/A).
Cells were washed twice, then resuspended in RPMI 1640
medium (Invitrogen) with 5% FBS. Splenocytes were overlaid
onto a Lympholyte M cushion (Cedarlane) and centrifuged for
30 min at 2500 rpm at room temperature. The buffy coat was
removed, resuspended in PBS/A, and washed twice. After the
last wash, cells were resuspended in AIM V medium, counted,
and adjusted to 1×107 cells/ml and 50 μl was plated into wells
of anti-IFN-γ antibody coated 96 well plates containing either
50 μl of peptide(s) to be tested, an irrelevant control influenza
virus hemagglutinin (HA) peptide (IYSTVASSL), or a no
peptide control. A pool of three 15-mer SIV MA/CA peptides
shown previously to be reactive with splenocytes from SIV
MA/CA immunized BALB/c mice were used at 2 μg/ml (Cat.
#5236, Cat. #5276, and Cat. #5285; NIH AIDS Repository;
Cecil et al., 2007). The plates were incubated for 18–24 h at
37 °C with 5% CO2. Plates were washed with chilled distilled
water, incubated on ice for 10 min, washed 10 times with wash
buffer (PBS with 0.01% Tween-20), and then incubated with
1 μg/ml of biotinylated antibody to mouse IFN-γ (Mabtech,
R4-64A2) in PBS containing 0.01% Tween-20, 1% bovine
serum albumin (BSA) for 16–18 h at 4 °C. Plates were
washed 10 times with wash buffer. Strepavidin-alkaline
phosphatase (Mabtech) was diluted 1:1000 in PBS/0.01%
Tween-20/1% BSA, 100 μl was added to each well, and plates
were incubated for 1–2 h at room temperature. Plates were
washed 10 times, and spots were developed with 100 μl of
BCIP/NBT substrate (Promega) prepared according to the
manufacturer's instructions. Spots were counted using an
automated plate reader with ImmunoSpot software (Cellular
Technology Ltd.).
Serum IgG ELISA
His-tagged MA/CA protein was made in Escherichia coli
strain BL21DE3 using the pET24a expression plasmid. Ninety-
six well plates (Immulon-4, Thermo Electron) were coated with
200 ng/well of MA/CA-his protein in carbonate buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.6) and incubated overnight at
4 °C. Sera were diluted in PBS with 0.05% Tween and 10%
Sigmablock (Sigma) and added to plates for 2 h at room
temperature. Plates were washed and incubated with horse-
radish peroxidase-linked anti-mouse IgG (Sigma) for 2 h. Plates
were washed and then developed with o-Phenylenediamine
substrate (Sigma) for 30 min, followed by an acid-stop with
0.1 M sodium fluoride. Titers represent the serum dilution that
corresponded to half the maximum absorbance for each sample
measured at 450 nm.
Statistical analysis of ELISPOT and ELISA results
The Wilcoxon rank-sum test (using Van der Waerden normal
scores) was used for our numerous two-group comparisons. The
31M.E. Fluet et al. / Virology 370 (2008) 22–32Bonferroni method was used to adjust p-values to account for
multiple comparisons. Statistical analyses were performed with
SAS statistical software, Version 9.1, SAS Institute Inc., Cary,
NC.
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